51. Westermark GT, Steiner DF, Gebre-Medhin S, Engström U, Westermark P. Pro islet amyloid polypeptide (proIAPP) immunoreactivity in amyloid formation in the islets of Langerhans. Ups J Med Sci. 2000;105:97–106. 52. Paulsson JF, Westermark GT. Aberrant processing of human proislet amyloid polypeptide results in increased amyloid production. Diabetes. 2005;54:2117–25. 53. Mulder H, Ahrén B, Sundler F. Islet amyloid polypeptide and insulin gene expression are regulated in parallel by glucose in vivo in rats. Am J Physiol. 1996;271:E1008–14. 54. Westermark P, Li Z-C, Westermark GT, Leckström A, Steiner DF. Effects of beta cell granule components on human islet amyloid polypeptide ﬁbril formation. FEBS Lett. 1996; 379:203–6. 55. Janciauskiene S, Eriksson S, Carlemalm E, Ahrén B. b cell granule peptides affect human islet amyloid polypeptide (IAPP) ﬁbril formation in vitro. Biochem Biophys Res Com- mun. 1997;236:580–5. 56. Jaikaran ETAS, Nilsson MR, Clark A. Pancreatic b-cell gran- ule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide ﬁbril formation. Biochem J. 2004; 377:709–16. 57. Kisilevsky R, Ancsin JB, Szarek WA, Petanceska S. Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid. 2007;14:21–32. 58. Westermark P, Skinner M, Cohen AS. The P-component of amyloid of human islets of Langerhans. Scand J Immunol. 1975;4:95–7. 59. Coker AR, Purvis A, Baker D, Pepys MB, Wood SP. Molec- ular chaperone properties of serum amyloid P component. FEBS Lett. 2000;473:199–202. 60. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC. The mechanism of islet amyloid polypeptide toxicity is mem- brane disruption by intermediate-sized toxic amyloid particles. Diabetes. 1999;48:491–8. 61. Dobson CM. Principles of protein folding, misfolding and aggregation. Semin Cell Develop Biol. 2004;15:3–16. 62. Hellman B. Pulsatility of insulin release—a clinically impor- tant phenomenon. Ups J Med Sci. 2009;114:193–205. 63. Juhl CB, Pørksen N, Sturis J, Hansen AP, Veldhuis JD, Pincus S, et al. High-frequency oscillations in circulating amylin concentrations in healthy humans. Am J Physiol Endo- crinol Metab. 2000;278:E484–90. 64. Jurgens CA, Toukatly MN, Fligner CL, Udayasankar J, Subramanian SL, Zraika S, et al. Beta-cell loss and beta-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Path. 2011. In press. Amyloid in the islets of Langerhans 89 65. Guardado-Mendoza R, Davalli AM, Chavez AO, Hubbard GB, Dick EJ, Majluf-Cruz A, et al. Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci U S A. 2009;106:13992–7. 66. Maclean N, Ogilvie RF. Quantitative estimation of the pancre- atic islet tissue in diabetic subjects. Diabetes. 1955;4:367–76. 67. Gepts W. Die histopatohlogischen Veränderungen der Langerhansschen Inseln und ihre Bedeutung in der Frage der Pathogenese des menschlichen Diabetes. Endokrinologie. 1958;36:185–211. 68. Klöppel G, Drenck CR. Immunzytochemische Morphometrie beim Typ-1- und Typ-2-Diabetes mellitus. Deutsch Med Wschr. 1983;108:188–9. 69. Westermark P, Wilander E. The inﬂuence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Dia- betologia. 1978;15:417–21. 70. Westermark P, Grimelius L. The pancreatic islet cells in insular amyloidosis in human diabetic and non-diabetic adults. Acta Path Microbiol Scand A. 1973;81:291–300. 71. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, et al. Islet amyloid, increased A-cells, reduced B-cells and exocrine ﬁbrosis: quantitative changes in the pancreas in type 2 diabetes. Diab Res. 1988;9:151–9. 72. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10 Suppl 4:32–42. 73. Hoenig M. The cat as a model for human nutrition and disease. Curr Opin Clin Nutr Metab Care. 2006;9:584–8. 74. Carlsson P-O. Inﬂuence of microenvironment on engraftment of transplanted b-cells. Ups J Med Sci. 2011;116:1–7. 75. Andersson A, Borg H, Groth CG, Gunnarsson R, Hellerström C, Lundgren G, et al. Survival of isolated human islets of Langerhans maintained in tissue culture. J Clin Invest. 1976;57:1295–301. 76. Westermark GT, Westermark P, Nordin A, Törnelius E, Andersson A. Formation of amyloid in human pancreatic islets transplanted to the liver and spleen of nude mice. Ups J Med Sci. 2003;108:193–204. 77. Westermark P, Andersson A, Westermark GT. Is aggregated IAPP a cause of beta-cell failure in transplanted human pancreatic islets? Curr Diab Rep. 2005;5:184–8. 78. Westermark GT, Westermark P, Berne C, Korsgren O. Widespread amyloid deposition in transplanted human pancreatic islets. N Engl J Med. 2008;359:977–9. 79. Porte D Jr. Banting lecture 1990. b-cells in type II diabetes mellitus. Diabetes. 1991;40:166–80.